Other Information
−Removed: Rosty Raykov , a current member of our Board of Directors , adopted a trading arrangement on September 19, 2025 , which is intended to satisfy the Rule 10b5-1 affirmative defense.
−Removed: This trading arrangement covers the disposition of up to 109,184 shares of the Company’s common shares, and will terminate on June 9, 2026 , unless earlier terminated in accordance with its terms.
−Removed: No additional directors or officers informed us of the adoption, modification or termination of a “ Rule 10b5-1 trading arrangement” or “non- Rule 10b5-1 trading arrangement ,” as those terms are defined in Regulation S-K, Item 408.
−Removed: On November 13, 2025, we issued a press release announcing our financial results for the quarter ended September 30, 2025.
+Added: Insider Trading Arrangements and Policies
+Added: During the quarter ended March 31, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulations S-K.
+Added: Press Release
+Added: On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026.
A copy of the news release is attached to this Quarterly Report as Exhibit 99.1.
−Removed: The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.
+Added: The press release is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or
+Added: incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references the press release.
+Added: Fennec Pharmaceuticals Inc.
+Added: 2026 Equity Inducement Plan (incorporated herein by reference to Schedule B to the Management Proxy Circular of the Company filed April 28, 2026).
Certification of Chief Executive Officer of the Company in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
1 unchanged sentence
Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
−Removed: Press Release for Quarter September 30, 2025 (filed herewith).
+Added: Press Release for Quarter Ended March 31, 2026 (filed herewith).
Inline XBRL Instance Document
6 unchanged sentences
information contained in Exhibits 101)
+Added: * Indicates a management contract or compensatory plan.
Pursuant to requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Fennec Pharmaceuticals Inc.
−Removed: November 13, 2025
−Removed: /s/ Jeff Hackman
+Added: /s/ Jeffrey Hackman
+Added: Jeffrey Hackman
Chief Executive Officer
(principal executive officer)
−Removed: November 13, 2025
/s/ Robert Andrade
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.